Q BioMed Inc. announced that it has received a confirmed $500,000 order for Strontium Chloride USP Injections under a recently inked supply contract between Q BioMed, isoSolutions Marketing and Management and Chinese radiopharmaceutical company, Chengdu Syncor Pharmaceutical Co. Ltd. The agreement is the first of what is expected to be a high-growth named patient opportunity to supply Strontium89 in the Chinese market. Chengdu Syncor is an A-list radiopharmaceuticals supplier founded by Cadillac (United States) in 1999, devoted to providing high-quality radionuclide products to its customers throughout China.

The Chinese market is currently demanding 12,000 doses a year (growing 10% a year) from 2 local government run manufacturers. This order represents a small fraction of that opportunity. QBioMed expects to begin shipping doses in April once all logistics are in place and will continue through 2023.